VistaGen Therapeutics Inc (VTGN)

[Johnny_C]

I think oral ketamine is not going to be a winner as tested. Maybe they can redo trials like VTGN is doing with AV-101. Intravenous ketamine has short term benefits but the delivery method and then wait time after dosage makes that a hard sell.

Drug trials are very risky, especially trials trying to treat depression and anxiety. VTGN oral and nasal seem to have a fantastic safety profile. If Av-101 new compound meets data points in a new phase 2 trial and the nasal SAD meets data points the sky is the limit here. It will be great to be part of a drug without side effects that can help millions with mental health issues, whether it is anxiety or depression.

As a recent example of how difficult drug trials are my old neighbor protected and tried to reincarnate a non opiod drug that Pfizer tried numerous times to get approved over a 16 year period. He must be bummed out now.

VTGN AV-101 originally was tested for pain and met endpoints in early studies. It may be on the shelf now but that is another potential blockbuster indication VTGN has in the portfolio.

A pair of FDA advisory committees has rejected a risk mitigation proposal from Pfizer for its NGF-blocker tanezumab, stating it would fail to ensure the drug's benefits outweigh its risks for patients with osteoarthritis